REGOSARC: Regorafenib versus placebo in doxorubicin‐refractory soft‐tissue sarcoma—A quality‐adjusted time without symptoms of progression or toxicity analysis

BACKGROUND: In a placebo‐controlled, randomized phase 2 trial (ClinicalTrials.gov identifier NCT01900743), regorafenib improved progression‐free survival (PFS) for patients with doxorubicin‐pretreated advanced nonadipocytic sarcoma. A quality‐adjusted time without symptoms of progression or toxicity...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer
Main Authors: Berry, Vincent, Basson, Laurent, Bogart, Emilie, Mir, Olivier, Blay, Jean‐Yves, Italiano, Antoine, Bertucci, François, Chevreau, Christine, Clisant‐Delaine, Stéphanie, Liegl‐Antzager, Bernadette, Tresch‐Bruneel, Emmanuelle, Wallet, Jennifer, Taieb, Sophie, Decoupigny, Emilie, Le Cesne, Axel, Brodowicz, Thomas, Penel, Nicolas
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2017
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5485075/
https://ncbi.nlm.nih.gov/pubmed/28295221
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.30661
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados